<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Medical Sciences Division</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EFD541EC-F53F-4F79-BFA5-8DCE70466421"><gtr:id>EFD541EC-F53F-4F79-BFA5-8DCE70466421</gtr:id><gtr:firstName>A</gtr:firstName><gtr:otherNames>Neil</gtr:otherNames><gtr:surname>Barclay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9826026"><gtr:id>3107A3A0-79B2-4DE5-9DC5-EF0039F6D45E</gtr:id><gtr:title>The molecular basis for CD200R and SIRP paired receptor family function</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9826026</gtr:grantReference><gtr:abstractText>The immune system is remarkable in that it can recognise foreign materials such as bacteria and viruses without having encountered them before and make a measured response that leads to their elimination. It can distinguish between small infections at the site of, for example a bite, from a viral infection like influenza that calls for all the power of the immune system to be mobilised. This control is mediated by white blood cells patrolling the body waiting to react. The nature of the responses is highly controlled and this involves interactions of proteins at the surface of the blood cells with other cells. This proposal looks at one class of proteins called paired receptors that have been implicated in virus defence and have the intriguing property that they can give very different signals although the bit that recognises other cells is quite similar. These paired receptors are evolving very fast and the hypothesis is that bacteria and viruses might bind them directly and therefore affect responses to them and also the immune system in general. The aim is to understand the mechanisms involved at a molecular level for this interaction. The use of quantitative molecular analysis in this study will identify parameters involved in determining the signal produced with relevance for therapies involving this type of target and for the general understanding of the immune system. Thus it will have implications in understanding and treating diseases like cancer, infectious diseases and autoimmune disease such as arthritis, diabetes.</gtr:abstractText><gtr:technicalSummary>Paired receptors are families of membrane proteins with similar extracellular regions but different intracellular sequences so that one member can give inhibitory signals whereas the others can give activating signals. In the two families that we have characterised, CD200R and SIRP, the ligands for the inhibitory receptors are widely distributed membrane proteins, CD200 and CD47 respectively and the activating receptor gives negligible binding to these. These protein families are evolving rapidly and the theory is that pathogens target the inhibitory receptor but activating receptors evolve to act as a counterbalance. They are implicated in regulation of immunity, neuropathology and cancer. The project will focus on the three aspects of the CD200R and SIRP families.
1. Screen these paired receptors for pathogen, and in particular, bacterial binding. The molecular nature of the binding partner on bacteria will be established for a characterised paired receptor (PIRA) and extended to CD200R and SIRPs. Do the polymorphisms in the receptor affect pathogen binding? If pathogens affect myeloid activity in this way, what happens when both activating and inhibitory receptors are targetted? How does this type of interaction modify the response? The uncharacterised genes in the SIRP cluster will be characterised for gene expression and ligand binding to ensure a comprehensive analysis of the family.
2. CD200R signals by a different mechanism from all other leukocyte inhibitory receptors in that it involves binding of DOK adaptors rather than recruiting phosphatases. In other respects CD200R and SIRPs are very similar being present on similar types of cells. We will apply new quantitative mass spectrometry phosphoproteomic analysis to determine the timecourse for phosphorylation of CD200R and down stream proteins. This should reveal proteins involved in the signalling pathway that can be tested by direct binding using recombinant proteins and RNAi in functional experiments. Comparable experiments will be carried out on SIRP alpha signalling to compare the DOK2 mediated signalling with conventional ITIM mediated phosphatase recruitment. 
3. Ligands for the SIRP and CD200R receptors have also been acquired by viruses indicating their importance in pathogen host responses. We will further characterise these. Does viral CD47 bind SIRP alpha and if not what does it interact with? Whilst viral CD200 from herpes virus 8 acts as a mimic, the homologues in other viruses do not appear to be typical membrane proteins so are they high affinity soluble ligands or do they act in another way such as association with other host/viral proteins?</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4591285</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The application of mass spectrometry to cells of the immune system indicates new ways in which regulation</gtr:description><gtr:id>1681C578-6050-4F58-9265-DBBE65A40E72</gtr:id><gtr:impact>These findings have impacts beyond the areas we can study and several collaborations or provision of ideas have taken place.</gtr:impact><gtr:outcomeId>GuDur6ZmoYv</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mass spectrometric methods to identify protein with labile disulfide bonds</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5942948A-1885-4922-A7D3-ED49B6E027FB</gtr:id><gtr:title>Immunoregulation through membrane proteins modified by reducing conditions induced by immune reactions.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67022c45a3e3d6e63ebd3f7e61a17bb2"><gtr:id>67022c45a3e3d6e63ebd3f7e61a17bb2</gtr:id><gtr:otherNames>Stegmann M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14072_22_23233323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B37DF0F2-2A15-4005-9E03-7911D572E745</gtr:id><gtr:title>Polymorphisms in the human inhibitory signal-regulatory protein a do not affect binding to its ligand CD47.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b18b8a2d6abc4fab7a4805d65e8c30"><gtr:id>49b18b8a2d6abc4fab7a4805d65e8c30</gtr:id><gtr:otherNames>Hatherley D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_540e17ee17ed7111d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A5398FC-8BE7-4EAC-817A-5F280149A968</gtr:id><gtr:title>OX130 Monoclonal Antibody Recognizes Human SIRP?1 but Cross-Reacts on SIRPa from One Allele.</gtr:title><gtr:parentPublicationTitle>Monoclonal antibodies in immunodiagnosis and immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b18b8a2d6abc4fab7a4805d65e8c30"><gtr:id>49b18b8a2d6abc4fab7a4805d65e8c30</gtr:id><gtr:otherNames>Hatherley D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-9436</gtr:issn><gtr:outcomeId>585d53d9f39a23.19468912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B46A8B5-1980-47ED-B9DB-E4B3C32C026F</gtr:id><gtr:title>Homodimerization of the Lymph Vessel Endothelial Receptor LYVE-1 through a Redox-labile Disulfide Is Critical for Hyaluronan Binding in Lymphatic Endothelium.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/448b5f7fd751cf272bebade77e3e8ec3"><gtr:id>448b5f7fd751cf272bebade77e3e8ec3</gtr:id><gtr:otherNames>Banerji S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5a2fd35c717eb2.69759620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6B16F48-0F42-4AA9-84AB-A2994D7D41D4</gtr:id><gtr:title>Crystal structure of signal regulatory protein gamma (SIRP?) in complex with an antibody Fab fragment.</gtr:title><gtr:parentPublicationTitle>BMC structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5083c27c32694a5a97d0d79ec526d5b9"><gtr:id>5083c27c32694a5a97d0d79ec526d5b9</gtr:id><gtr:otherNames>Nettleship JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1472-6807</gtr:issn><gtr:outcomeId>doi_55f985985df09592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3EB5E97-9935-4BA9-AE66-11FE22B5C5AA</gtr:id><gtr:title>OX133, a monoclonal antibody recognizing protein-bound N-ethylmaleimide for the identification of reduced disulfide bonds in proteins.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91986e5fa3e31d4133a81b3d7fed161a"><gtr:id>91986e5fa3e31d4133a81b3d7fed161a</gtr:id><gtr:otherNames>Holbrook LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn><gtr:outcomeId>585d6aaf520a86.04238434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37C7BD41-6883-41A6-9581-ACB39E1412F3</gtr:id><gtr:title>The interaction between signal regulatory protein alpha (SIRPa) and CD47: structure, function, and therapeutic target.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db46017da74e2d4b23371233a2fe3d6e"><gtr:id>db46017da74e2d4b23371233a2fe3d6e</gtr:id><gtr:otherNames>Barclay AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>pm_540e17ee17ecb4ebc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>143136CF-35E1-4FA2-9B94-25DBC2CE1981</gtr:id><gtr:title>How do pathogens drive the evolution of paired receptors?</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/254f024c16d865180d3aedd11b23fa3e"><gtr:id>254f024c16d865180d3aedd11b23fa3e</gtr:id><gtr:otherNames>Akkaya M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14072_22_23280392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>035BAA91-9627-4F5D-8471-223168C2FABE</gtr:id><gtr:title>Structures of CD200/CD200 receptor family and implications for topology, regulation, and evolution.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b18b8a2d6abc4fab7a4805d65e8c30"><gtr:id>49b18b8a2d6abc4fab7a4805d65e8c30</gtr:id><gtr:otherNames>Hatherley D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>pm_14072_22_23602662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAB8F2A6-39A9-4D94-A15D-F952EA2A591E</gtr:id><gtr:title>Dissection of agonistic and blocking effects of CD200 receptor antibodies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/254f024c16d865180d3aedd11b23fa3e"><gtr:id>254f024c16d865180d3aedd11b23fa3e</gtr:id><gtr:otherNames>Akkaya M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14072_22_23691022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F55A7FA-7DC7-41E5-AC5B-05B1D8D063EA</gtr:id><gtr:title>Rabbit CD200R binds host CD200 but not CD200-like proteins from poxviruses.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/254f024c16d865180d3aedd11b23fa3e"><gtr:id>254f024c16d865180d3aedd11b23fa3e</gtr:id><gtr:otherNames>Akkaya M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>585d557a465409.83216914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECCD0C7C-40C5-47F7-A1E6-070228E8F2E2</gtr:id><gtr:title>Thioredoxin Inhibitors Attenuate Platelet Function and Thrombus Formation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d61a8e019181cfb919b7ee6f4053188"><gtr:id>4d61a8e019181cfb919b7ee6f4053188</gtr:id><gtr:otherNames>Metcalfe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d3f42b69ae0.94603927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D203578D-A2E7-452F-A171-C336FCA76554</gtr:id><gtr:title>CD44 Binding to Hyaluronic Acid Is Redox Regulated by a Labile Disulfide Bond in the Hyaluronic Acid Binding Site.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7b1e4ced4d46ccb59be5713d08709d3"><gtr:id>d7b1e4ced4d46ccb59be5713d08709d3</gtr:id><gtr:otherNames>Kellett-Clarke H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675eba5245a3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61D2CA7F-93DC-4442-B715-7A233850C737</gtr:id><gtr:title>Cytomegalovirus e127 protein interacts with the inhibitory CD200 receptor.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4784013aea3e56dde1304901fb783389"><gtr:id>4784013aea3e56dde1304901fb783389</gtr:id><gtr:otherNames>Foster-Cuevas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>YBeGaYiBhR5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B358C2C4-3AF9-4870-8425-3CBADD3BABD8</gtr:id><gtr:title>Herpesvirus orthologues of CD200 bind host CD200R but not related activating receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79d6cf6f05e38cd8fc3236316623fcd8"><gtr:id>79d6cf6f05e38cd8fc3236316623fcd8</gtr:id><gtr:otherNames>Kwong LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>585d560b849987.80192648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD172877-F464-459C-9C80-F168CB65C52A</gtr:id><gtr:title>Signal-regulatory protein a from the NOD mouse binds human CD47 with an exceptionally high affinity-- implications for engraftment of human cells.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79d6cf6f05e38cd8fc3236316623fcd8"><gtr:id>79d6cf6f05e38cd8fc3236316623fcd8</gtr:id><gtr:otherNames>Kwong LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>doi_55f985985de7228f</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9826026</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>